Repligen Corporation announces Dr. Martin D. Madaus as new Chair of the Board, succeeding retiring Tony Hunt.
Quiver AI Summary
Repligen Corporation has appointed Dr. Martin D. Madaus as Chair of the Board, effective March 13, 2026, following the retirement of Tony Hunt, who has served as Executive Chair for over a decade and will continue as an advisor until March 2027. President and CEO Olivier Loeillot expressed gratitude for Hunt's contributions and confidence in Madaus's leadership, citing his extensive experience in bioprocessing and biopharmaceuticals. Dr. Madaus, who has been a director since February 2023 and previously led Millipore Corporation, expressed his honor in taking on the role and commended Hunt for his tenure. Repligen, based in Waltham, Massachusetts, specializes in innovative bioprocessing technologies that aid in the manufacturing of biological drugs.
Potential Positives
- Dr. Martin D. Madaus has been elected as the new Chair of the Board, bringing extensive industry experience and leadership that positions Repligen for continued success.
- The transition in leadership from Tony Hunt, who is stepping down after over a decade, is framed positively, highlighting a strong foundation and a clear path forward for growth.
- Olivier Loeillot, Repligen's President and CEO, expresses confidence in the new leadership team, which may reassure investors and stakeholders about the company’s strategic direction.
- Dr. Madaus’s prior success at Millipore Corporation, including its transformation and acquisition by Merck KGaA, suggests he may drive similar growth initiatives at Repligen.
Potential Negatives
- Transitioning leadership may create uncertainty among investors and stakeholders, as Tony Hunt's departure as Executive Chair marks a significant change in the company's governance.
- Dr. Martin D. Madaus's relatively short tenure on the board (since February 2023) raises questions about his preparedness to lead the company effectively as Chair.
- The press release emphasizes the retirement of a long-serving leader, which could lead to concerns about the company's future direction and continuity of strategy.
FAQ
Who has been elected as Chair of the Repligen Board?
Dr. Martin D. Madaus has been elected as Chair of the Repligen Board, effective March 13, 2026.
What role is Tony Hunt retiring from at Repligen?
Tony Hunt is retiring from his role as Executive Chair and a member of the Board of Directors.
When will Tony Hunt continue to advise Repligen?
Tony Hunt will serve as an advisor to Repligen through March 2027.
What is Dr. Madaus’s experience in the biopharma industry?
Dr. Madaus has 36 years of industry experience, including leadership roles at Millipore Corporation.
What does Repligen Corporation specialize in?
Repligen Corporation specializes in developing innovative bioprocessing technologies for manufacturing biological drugs.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$RGEN Insider Trading Activity
$RGEN insiders have traded $RGEN stock on the open market 22 times in the past 6 months. Of those trades, 1 have been purchases and 21 have been sales.
Here’s a breakdown of recent trading of $RGEN stock by insiders over the last 6 months:
- ANTHONY HUNT has made 0 purchases and 18 sales selling 74,111 shares for an estimated $10,522,606.
- OLIVIER LOEILLOT (Chief Executive Officer) sold 7,041 shares for an estimated $1,196,970
- JAMES BYLUND (Chief Operating Officer) sold 2,191 shares for an estimated $331,301
- MARTIN D MADAUS purchased 1,800 shares for an estimated $201,830
- KAREN A DAWES sold 275 shares for an estimated $44,275
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$RGEN Revenue
$RGEN had revenues of $188.8M in Q3 2025. This is an increase of 21.91% from the same period in the prior year.
You can track RGEN financials on Quiver Quantitative's RGEN stock page.
$RGEN Congressional Stock Trading
Members of Congress have traded $RGEN stock 4 times in the past 6 months. Of those trades, 2 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $RGEN stock by members of Congress over the last 6 months:
- REPRESENTATIVE LISA C. MCCLAIN has traded it 4 times. They made 2 purchases worth up to $30,000 on 10/30, 07/22 and 2 sales worth up to $30,000 on 10/31, 10/30.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
$RGEN Hedge Fund Activity
We have seen 233 institutional investors add shares of $RGEN stock to their portfolio, and 210 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- PRICE T ROWE ASSOCIATES INC /MD/ removed 3,096,576 shares (-46.9%) from their portfolio in Q3 2025, for an estimated $413,919,313
- UNITED CAPITAL FINANCIAL ADVISORS, LLC added 2,755,943 shares (+inf%) to their portfolio in Q3 2025, for an estimated $368,386,900
- SANDS CAPITAL MANAGEMENT, LLC removed 1,251,088 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $167,232,932
- FMR LLC added 1,077,908 shares (+66.8%) to their portfolio in Q3 2025, for an estimated $144,083,962
- CITADEL ADVISORS LLC added 621,664 shares (+58.5%) to their portfolio in Q3 2025, for an estimated $83,097,826
- BALYASNY ASSET MANAGEMENT L.P. added 610,837 shares (+390.6%) to their portfolio in Q3 2025, for an estimated $81,650,581
- INVESCO LTD. removed 506,087 shares (-36.7%) from their portfolio in Q3 2025, for an estimated $67,648,649
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$RGEN Analyst Ratings
Wall Street analysts have issued reports on $RGEN in the last several months. We have seen 7 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Barclays issued a "Overweight" rating on 10/29/2025
- Evercore ISI Group issued a "Outperform" rating on 10/07/2025
- HSBC issued a "Buy" rating on 10/01/2025
- HC Wainwright & Co. issued a "Buy" rating on 09/03/2025
- RBC Capital issued a "Outperform" rating on 07/30/2025
- Wells Fargo issued a "Overweight" rating on 07/30/2025
- Stephens & Co. issued a "Overweight" rating on 07/22/2025
To track analyst ratings and price targets for $RGEN, check out Quiver Quantitative's $RGEN forecast page.
$RGEN Price Targets
Multiple analysts have issued price targets for $RGEN recently. We have seen 9 analysts offer price targets for $RGEN in the last 6 months, with a median target of $175.0.
Here are some recent targets:
- Luke Sergott from Barclays set a target price of $200.0 on 12/15/2025
- Brandon Couillard from Wells Fargo set a target price of $190.0 on 12/15/2025
- Kyle Mikson from Canaccord Genuity set a target price of $165.0 on 10/29/2025
- Daniel Markowitz from Evercore ISI Group set a target price of $175.0 on 10/07/2025
- Yessica Sanchez from HSBC set a target price of $150.0 on 10/01/2025
- Matthew Stanton from Jefferies set a target price of $135.0 on 09/12/2025
- Raghuram Selvaraju from HC Wainwright & Co. set a target price of $180.0 on 09/03/2025
Full Release
WALTHAM, Mass., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that the Board has elected Dr. Martin D. Madaus as Chair of the Board, effective March 13, 2026. As previously communicated 1 , Tony Hunt is retiring from his role as Executive Chair and member of the Board of Directors effective this March 13th. Mr. Hunt will continue to serve as an advisor to Repligen through March 2027.
“On behalf of Repligen, I want to thank Tony for over a decade of service to the Company, during which he expanded our unique and diversified portfolio of innovative products,” said Olivier Loeillot, Repligen President and CEO. “He left a strong foundation for us to build upon, and with Martin assuming the role of Chair of the Board, we are well-positioned for success. Martin’s deep expertise and strong leadership in bioprocessing and biopharma makes him exceptionally qualified to lead our Board.”
Dr. Martin D. Madaus added, “On behalf of the Board of Directors, our shareholders, employees, and other stakeholders, I want to commend Tony on his impressive tenure at Repligen. I am honored to be elected as Chair of the Repligen Board and look forward to guiding Repligen towards new heights.”
Tony Hunt said, “After more than a decade of leadership, I leave this Company immensely proud of the business we have created together. One that is rooted in clear strategy, disciplined execution and outstanding people. It has been a privilege and an honor to work alongside such a committed team, and I leave knowing the Company is in very capable hands. I am confident that Olivier and Martin will build on the success we have enjoyed and lead Repligen to a new phase of growth.”
Martin D. Madaus, D.V.M., Ph.D., has served as a director of Repligen since February 2023. Dr. Madaus has 36 years of industry experience, including five years as Chairman, President and CEO of Millipore Corporation, where he was integral to the company’s transformation into a life science leader, and its acquisition by Merck KGaA in 2010. Dr. Madaus serves on the boards of Azenta, Inc. and Hologic, Inc. He holds a D.V.M. from the University of Munich in Germany and a Ph.D. from the University of Veterinary Medicine of Hanover in Germany.
About Repligen Corporation
Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. We are “inspiring advances in bioprocessing” for the customers we serve; primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Our corporate headquarters are located in Waltham, Massachusetts, and the majority of our manufacturing sites are in the U.S., with additional key sites in Estonia, France, Germany, Ireland, the Netherlands and Sweden. For more information about the our company see our website at www.repligen.com , and follow us on LinkedIn .
This press release may contain forward-looking statements within the meaning of the federal securities laws. Investors are cautioned that statements in this press release which are not strictly historical statements including, without limitation, statements identified by words like “believe,” “expect,” “may,” “will,” “should,” “seek,” or “could” and similar expressions, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including risks discussed from time to time in our filings with the Securities and Exchange Commission. We expressly disclaim any responsibility to update any forward-looking statements, except as required by law.
Repligen Contact:
Jacob Johnson
VP, Investor Relations
781-419-0204
[email protected]
________________________
1
Repligen June 14, 2024 8-K
